Innovators Circle: Operationalizing Risk Management in the QMSR Era

FDA inspections are increasingly evaluating risk management as an enterprise-wide management system rather than a narrowly focused technical activity. Recent analysis of FDA Form 483 observations demonstrates a notable shift in how investigators assess organizational effectiveness, with growing emphasis on how risk is integrated throughout the Quality Management System (QMS).

In this Risk Management Innovators Circle session, industry leaders will examine emerging FDA inspection trends and discuss recent Form 483 observations related to risk management. Speakers will explore evolving FDA expectations, including how investigators assess risk management practices, management oversight, and the effectiveness of risk-based decision-making across the product lifecycle.

The discussion will highlight the implications of the FDA’s Quality Management System Regulation (QMSR), emphasizing that while QMSR does not introduce entirely new requirements, it reinforces the need for organizations to consistently implement, integrate, and sustain established risk management principles. Participants will also explore how emerging technologies, including artificial intelligence, fit within this evolving framework and discuss the importance of validation, human oversight, data integrity, and risk-based controls.

Attendees will gain practical insights into current regulatory expectations, understand common gaps identified during inspections, and learn strategies for leveraging AI responsibly to enhance risk management processes, strengthen decision-making, improve operational efficiency, and support compliance, product quality, and organizational performance.

Key Takeaways:

• Insights from analysis of the most recent FDA 483 findings
  The shift from “risk as a technical task” to “risk as a management system”
• Integration of risk into QMS processes and total product lifecycle activities
• Leveraging feedback loops and real-world signals as risk inputs
• What FDA is now assessing: whether organizations truly operate by risk
• AI within the QMS: applying risk-based validation and human oversight
• Human-in-the-loop controls as mitigations for model influence risk
• Training, model performance metrics, and drift monitoring as assurance activities
• Supplier quality and risk maturity considerations across the value chain